{
    "2019-08-16": [
        [
            {
                "time": "2018-01-02",
                "original_text": "How AbbVie Plans To Take On Pfizer, Lilly — And Kick Its Humira Habit",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Pfizer",
                        "Lilly",
                        "Humira"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-03",
                "original_text": "How Merck Could Ride 'The Keytruda Wave' To Dominate These Rivals",
                "features": {
                    "keywords": [
                        "Merck",
                        "Keytruda",
                        "rivals"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-08-16",
                "original_text": "FDA approves AbbVie's Rinvoq to treat moderate-to-severe RA",
                "features": {
                    "keywords": [
                        "FDA",
                        "AbbVie",
                        "Rinvoq",
                        "RA"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-08-16",
                "original_text": "UPDATE 2-AbbVie prices new rheumatoid arthritis drug at $59,000/yr",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "rheumatoid arthritis",
                        "drug",
                        "price"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "mixed"
                }
            },
            {
                "time": "2019-08-16",
                "original_text": "AbbVie Receives FDA Approval of RINVOQ™ (upadacitinib), an Oral JAK Inhibitor For The Treatment of Moderate to Severe Rheumatoid Arthritis",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "FDA",
                        "RINVOQ",
                        "JAK",
                        "RA"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-07-15",
                "original_text": "Gilead's (GILD) Filgotinib MAA for RA Accepted in Europe",
                "features": {
                    "keywords": [
                        "Gilead",
                        "Filgotinib",
                        "MAA",
                        "RA",
                        "Europe"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}